Option chain shows key data for China SXT Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for China SXT Pharmaceuticals.

China SXT Pharmaceuticals (NASDAQ:SXTC) Stock, Option Chain

China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALBT

AUMN

BIOA

ESSA

GXAI

HCTI

ORIS

RENT

RIME

SATL

SBET

SPCB

SXTC

ZBAO

Why Interpublic Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

movers image

AILE

ALTM

BKYI

CNEY

FTCI

MPLN

PLAY

RLAY

SLXN

TANH

TBIO

TOMZ

Why Dave &amp; Buster&#39;s Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket

Intraday Update

ACHR

AGRI

ASPI

BDRX

BILI

CGBS

COCO

ERIC

EVGO

EYPT

FWRD

HOVR

IMMP

KZIA

LCFY

LCID

LIPO

NISN

PEGY

Qualigen Therapeutics, Inc. - Common Stock

QLGN

RNLX

SANW

SISI

SNTG

TOYO

VALU

VRPX

VSTM

YGMZ

ZAPP

Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals Inc

Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) has outperformed the market over the past 10 years by 4.78% on an annualized basis producing an average annual return of 15.78%. Currently, Burlington Stores has a market capitalization of $14.84 billion. 
Buying $1000 In BURL: If an investor had bought $1000 of BURL stock 10 years ago, it would be worth $4,359.22 today based on a price of $233.80 for BURL at the time of writing.
<h3>Burlington Stores's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740180608_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BURL

Here's How Much You Would Have Made Owning Burlington Stores Stock In The Last 10 Years

East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) has outperformed the market over the past 5 years by 4.19% on an annualized basis producing an average annual return of 18.12%. Currently, East West Bancorp has a market capitalization of $13.00 billion. 
Buying $1000 In EWBC: If an investor had bought $1000 of EWBC stock 5 years ago, it would be worth $2,161.37 today based on a price of $93.89 for EWBC at the time of writing.
<h3>East West Bancorp's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740179709_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

EWBC

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) has outperformed the market over the past 15 years by 8.84% on an annualized basis producing an average annual return of 20.69%. Currently, Costco Wholesale has a market capitalization of $459.45 billion. 
Buying $100 In COST: If an investor had bought $100 of COST stock 15 years ago, it would be worth $1,697.61 today based on a price of $1035.03 for COST at the time of writing.
<h3>Costco Wholesale's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740178810_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COST

$100 Invested In Costco Wholesale 15 Years Ago Would Be Worth This Much Today

Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) has outperformed the market over the past 20 years by 8.72% on an annualized basis producing an average annual return of 17.04%. Currently, Taiwan Semiconductor has a market capitalization of $1.03 trillion. 
Buying $1000 In TSM: If an investor had bought $1000 of TSM stock 20 years ago, it would be worth $23,508.40 today based on a price of $198.00 for TSM at the time of writing.
<h3>Taiwan Semiconductor's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740177909_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Taiwan Semiconductor 20 Years Ago Would Be Worth This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-02-21/blackstone-nears-1-7-billion-deal-for-summit-backed-vaxcare" title="https://www.bloomberg.com/news/articles/2025-02-21/blackstone-nears-1-7-billion-deal-for-summit-backed-vaxcare">https://www.bloomberg.com/news/articles/2025-02-21/blackstone-nears-1-7-billion-deal-for-summit-backed-vaxcare</a>

'Blackstone Nears $1.7B Deal for Summit-Backed VaxCare' - Bloomberg News

Coca-Cola Consolidated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>) has outperformed the market over the past 15 years by 11.93% on an annualized basis producing an average annual return of 23.78%. Currently, Coca-Cola Consolidated has a market capitalization of $12.11 billion. 
Buying $100 In COKE: If an investor had bought $100 of COKE stock 15 years ago, it would be worth $2,484.92 today based on a price of $1382.86 for COKE at the time of writing.
<h3>Coca-Cola Consolidated's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740177024_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COKE

Here's How Much You Would Have Made Owning Coca-Cola Consolidated Stock In The Last 15 Years

Cryptocurrency markets are trading lower on Friday after a $1.4 billion hack on Bybit dragged down the market.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>$95,385.38</td>
<td>-3.1%</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>$2,634.96</td>
<td>-4.3%</td>
</tr>
<tr>
<td>Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>)</td>
<td>$168.78</td>
<td>-3.5%</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>$2.52</td>
<td>-6.9%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2400</td>
<td>-5.6%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001494</td>
<td>-4%</td>
</tr>
</tbody>
</table>
</figure>
Notable Statistics:
<ul>
<li>IntoTheBlock data shows large transaction volume increasing by 12.3% and daily active addresses growing by 4%. Transactions greater than $100,000 are up from 9,587 to 9,988 in a single day. Exchanges netflows are up by 105.3%.</li>
<li>Coinglass data reports 188,950 traders were liquidated in the past 24 hours for $551.47 million.</li>
</ul>
Notable Developments:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43886224/bybit-founder-confirms-1-4-billion-ethereum-hack-blames-masked-transaction">Bybit Founder Confirms $1.4 Billion Ethereum Hack, Blames &#8216;Masked&#8217; Transaction</a></li>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43883117/coinbase-ceo-brian-armstrong-says-sec-has-agreed-to-end-bogus-enforcement-case-without-penalties">Coinbase CEO Brian Armstrong Says SEC Has Agreed To End &#8216;Bogus&#8217; Enforcement Case Without Penalties</a></li>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43887659/coinbase-shares-rise-as-sec-moves-to-drop-lawsuit-whats-going-on">Coinbase Shares Rise As SEC Moves To Drop Lawsuit: What&#8217;s Going On?</a></li>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43878748/michael-saylor-bitcoin-is-economic-armor-calls-on-us-to-accumulate-btc">Michael Saylor: &#8216;Bitcoin Is Economic Armor&#8217;, Calls On US To Accumulate BTC</a></li>
<li><a href="https://www.benzinga.com/25/02/43876426/new-fbi-director-kash-patel-holds-over-100000-in-bitcoin-etfs-has-significant-exposure-to-btc-miner-core-scientific">New FBI Director Kash Patel Holds Over $100,000 In Bitcoin ETFs, Has Significant Exposure To BTC Miner Core Scientific</a></li>
</ul>
Top Gainers:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Gains +/-</td>
</tr>
<tr>
<td>Story (CRYPTO: IP)</td>
<td>&nbsp;$4.51</td>
<td>+17.8%</td>
</tr>
<tr>
<td>Jito (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">JTO</a>)</td>
<td>&nbsp;$3.04</td>
<td>+11.7%</td>
</tr>
<tr>
<td>Bitget Token (CRYPTO: BGB)</td>
<td>&nbsp;$4.67</td>
<td>+3%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: More Crypto Online <a href="https://x.com/Morecryptoonl/status/1892996131896074459">noted</a> that Bitcoin has confirmed a local top, aligning with broader market trends. The price failed to sustain above the Feb. 14 high. For a bullish continuation, it should hold above $94,645 in this potential wave 2. The key invalidation level is $93,450.
Crypto trader CJ explained Bitcoin has tagged last week&#8217;s high and low. It provided clean trades on both sides of the range. The trader awaits to see if mid-range demand holds. Ideally, BTC ranges through the weekend.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/search?q=%24BTC&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$BTC</a> Previous week high and low tagged. Both sides of the range produced a very clean trade. Let&#39;s see if the mid-range demand holds or not. Ideally just range for the weekend. Notable strength on a couple alts here e.g. ENA &#x1f37f; <a href="https://t.co/d8TtHjecRz">pic.twitter.com/d8TtHjecRz</a>
&mdash; CJ (@CJ900X) <a href="https://twitter.com/CJ900X/status/1893001814422802655?ref_src=twsrc%5Etfw">February 21, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Crypto trader Jelle reaffirmed his expectations and <a href="https://x.com/CryptoJelleNL/status/1893015465988944344">predicts</a> that market looks good for a strong end to the month.
Read Next:&nbsp;
<ul>
<li><a href="https://in.benzinga.com/markets/cryptocurrency/25/02/43889897/bitcoin-strategic-reserve-with-1-million-btc-could-offset-21-trillion-national-debt">Bitcoin Reserve With 1 Million BTC Could Offset $21 Trillion National Debt By 2049, Expert Says</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BGB

$BTC

$DOGE

$ETH

$JTO

$SHIB

$SOL

$XRP

Bitcoin, Ethereum, XRP, Dogecoin See Friday Blues After Massive $1.4 Billion Bybit Hack

Hooters of America is huddling up with its creditors to cook up a <a href="https://www.benzinga.com/topic/bankruptcy">bankruptcy restructuring plan</a>. 
The famous BBQ wing chain has enlisted legal heavyweights at Ropes &amp; Gray to prep the filing, according to <a href="https://www.bloomberg.com/news/articles/2025-02-21/hooters-in-talks-to-prepare-a-bankruptcy-filing-in-coming-months?srnd=homepage-americas&amp;sref=TBDibEcD">Bloomberg</a>. The court showdown could kick off within the next two months.
Known for its crop-top uniforms and winking owl mascot, Hooters is trying to get its financial house in order with help from turnaround pros at boutique firm Accordion Partners. 
Meanwhile, some of its lenders have brought in Houlihan Lokey to also advise the process.
<h2 class="wp-block-heading">What Else Is On The Bankruptcy Block?</h2>
Hooters isn&#8217;t the only sit-down dining spot feeling the heat of Chapter 11. 
Mediterranean fast-casual chain Rōti, for example, recently sold out of bankruptcy. According to <a href="https://www.chicagobusiness.com/restaurants/roti-sold-out-bankruptcy-edible-arrangements-founder">Crain&#8217;s Chicago</a>, a private-equity firm led by the founder of Edible Arrangements agreed to take it over. 
Rōti will retain 17 of its 19 locations once the deal is complete.
The culprit behind these filings? Fewer customers waltzing through doors thanks to <a href="https://www.emarketer.com/content/dining-inflation-remains-higher-than-food-home--forcing-restaurants-compete-on-value">inflation</a>. Plus, supply chain headaches, and soaring interest rates are pushing menu prices skyward. As a result, more folks are opting to cook at home. 
More than a dozen major restaurant groups or franchisees waved the white flag and filed for bankruptcy last year, including <a href="https://www.benzinga.com/news/24/05/38992673/the-craziest-parts-of-the-red-lobster-bankruptcy-story-revealed">Red Lobster</a> and <a href="https://www.benzinga.com/m-a/24/11/41700829/deal-dispatch-tgi-fridays-goes-bankrupt-bhp-backtracks-comments-and-more-m-a-news">TGI Fridays</a>. 
<h2 class="wp-block-heading">New On The Block</h2>
<ul>
<li>Family Dollar, a discount retailer owned by Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>), is for sale. Reuters reports that several buyout firms — Apollo Global Management, Sycamore Partners,and Brigade Capital Management — are interested.</li>
</ul>
<ul>
<li>HBM Healthcare Investments is shopping Baar, Switzerland-based Swixx Biopharma to potential buyers. Bloomberg put the valuation at about 1.5 billion Swiss francs ($1.7 billion). Jefferies Financial Group Inc. and Centerview Partners are handling <a href="https://www.bloomberg.com/news/articles/2025-02-20/hbm-is-said-to-consider-1-7-billion-sale-of-swixx-biopharma?sref=TBDibEcD">the sale</a>.</li>
</ul>
<h2 class="wp-block-heading">Updates From The Block</h2>
<ul>
<li>Italian media outlet Daily Il Sole 24 <a href="https://www.ilsole24ore.com/art/prada-stretta-versace-esclusiva-quattro-settimane-AGHcQc0C">reports</a> that Prada Group is actively trying to buy Versace. Investment bank Citi is reportedly advising Prada on a potential acquisition. Versace has been under the ownership of Capri Holdings since 2018. Since mid-December, speculation has been mounting that Capri is gearing up to sell Versace, along with another brand in its portfolio—Jimmy Choo. Barclays is advising Capri Holdings to circulate the dossier among potential buyers. This week, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-02-19/prada-works-with-advisers-to-evaluate-versace-for-possible-bid?srnd=phx-deals&amp;embedded-checkout=true&amp;sref=TBDibEcD">reported</a> that Prada has gained access to Versace&#8217;s latest financial and sales figures.</li>
</ul>
<ul>
<li>Carlyle Group, Thoma Bravo, and TA Associates have advanced to the final bidding round for French software firm SmartTrade Technologies, <a href="https://www.bloomberg.com/news/articles/2025-02-20/carlyle-thoma-bravo-shortlisted-in-bidding-for-smarttrade?sref=TBDibEcD">Bloomberg</a> reports. Current offers value the company at $577 million. Hg, SmartTrade's owner, aims to select a buyer by late March.</li>
</ul>
<ul>
<li>Private equity firms are also <a href="https://www.bloomberg.com/news/articles/2025-02-21/kkr-s-goodpack-sale-is-said-to-attract-apollo-i-squared-stonepeak?sref=TBDibEcD">lining up</a> for Goodpack, a Singapore-based logistics service provider. The price tag is expected to be about $1.5 billion. KKR &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) is on the sell side, while Apollo Global Management Inc., I Squared Capital and Stonepeak Partners are among the bidders.</li>
</ul>
<h2 class="wp-block-heading">Off The Block</h2>
<ul>
<li>Alani Nu, a female-focused energy drink brand, agreed to a deal with Celsius (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) for $1.8 billion. This is just the latest in a string of <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/06/27846252/could-pepsico-buyout-celsius-holdings-or-monster-beverage-why-m-a-in-energy-drinks-">energy drink deals</a>. Ghost belongs to Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) and Bang Energy is owned by Monster, and PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) purchased Rockstar Energy for $3.9 billion.</li>
</ul>
<ul>
<li>Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) <a href="https://www.businesswire.com/news/home/20250220946779/en/Greenbriar-Signs-Agreement-to-Sell-Breeze-Autocare-to-Valvoline">purchased</a> Breeze Autocare, an automotive maintenance services company, from Greenbriar Equity Group for $625 million. Breeze tapped Jefferies LLC and Piper Sandler &amp; Co. as financial advisors. Kirkland &amp; Ellis LLP handled legal matters. Morgan Stanley &amp; Co. LLC advised Lexington, Kentucky-based Valvoline on the purchase.</li>
</ul>
For last week&#8217;s edition of the <a href="https://www.benzinga.com/news/25/02/43749625/deal-dispatch-ny-giants-look-to-score-some-private-equity-plus-ma-volume-is-down">Deal Dispatch, click here</a>.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/real-estate/25/02/43886371/jason-statham-lists-beverly-hills-home-for-20-million-heres-a-look-at-the-british-action-heros-real-estate-portfolio">Action Hero Jason Statham Lists Beverly Hills Home For $20 Million</a></li>
</ul>
Image created using a photo from Shutterstock.

Asset Sales

CELH

DLTR

Deal Dispatch: Hooters Plans Restructuring, Prada In Talks To Acquire Versace

Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) has outperformed the market over the past 5 years by 9.96% on an annualized basis producing an average annual return of 23.88%. Currently, Chart Industries has a market capitalization of $7.79 billion. 
Buying $1000 In GTLS: If an investor had bought $1000 of GTLS stock 5 years ago, it would be worth $2,719.75 today based on a price of $181.87 for GTLS at the time of writing.
<h3>Chart Industries's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740176109_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GTLS

Here's How Much You Would Have Made Owning Chart Industries Stock In The Last 5 Years

Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) more than doubled its bonus plan for company executives after announcing layoffs for about 3,600 <a href="https://www.benzinga.com/25/02/43874069/meta-slashes-employee-stock-awards-by-10-as-zuckerberg-pours-up-to-65-billion-into-ai-race-against-openai-alphabet-and-amazon-report">employees just last month.&nbsp;</a>
The Details: According to an SEC <a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1326801/000132680125000021/meta-20250213.htm">filing</a>, on Feb. 13, Meta approved a new bonus structure that raises the annual target bonus amount from 75% of each named executive officer's base salary to 200% of the base salary. 
The bonus structure excludes CEO Mark Zuckerberg, according to the filing. 
Read Next: <a href="https://www.benzinga.com/general/market-summary/25/02/43884153/us-services-drop-sharply-darkening-picture-of-high-prices-uncertainty-economist-says">US Services Drop Sharply: &#8216;Darkening Picture&#8217; Of High Prices, Uncertainty, Economist Says</a>
The move to increase bonuses for Meta's executives comes after the company announced in January that it would be cutting 5% of its workforce. That&#8217;s about 3,600 employees. 
Meta described the cuts as "performance terminations" aimed at improving efficiency.
&#8220;I&#8217;ve decided to raise the bar on performance management and move out low-performers faster,&#8221; Zuckerberg wrote in an internal memo published by Bloomberg.&nbsp;
Former Meta employees<a href="https://www.benzinga.com/25/02/43723246/meta-faces-backlash-as-laid-off-workers-say-they-were-unfairly-targeted-despite-strong-performance-records"> spoke out</a> on social media. They claim that some high performers, including those on parental and medical leave, were unfairly targeted in the layoffs.  
&#8220;Meta is now the cruelest tech company out there,&#8221; a former employee posted on Blind, an anonymous forum for tech industry insiders.&nbsp;
The backlash does seem to have affected Meta's stock, <a href="https://www.benzinga.com/25/02/43806703/mark-zuckerbergs-meta-platforms-dips-below-short-term-average-as-it-snaps-20-day-winning-run">which ran</a> on a 20-day winning streak just after the layoffs were announced. 
In the 20 trading sessions between Jan. 16 to Feb. 14, Meta's stock rose 20.22%, and the company added over $350 billion in market capitalization during this period.
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Meta shares ended Friday's session down 1.62% at $683.55 amid a broad market selloff. 
Read Next:<a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch">&nbsp;</a>
<ul>
<li><a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch">Trump Administration Orders Sweeping Pentagon Cuts: Palantir, Lockheed Martin, General Dynamics Among Stocks On Watch</a></li>
</ul>
Image: Shutterstock

Large Cap

Social Media

General

Meta Follows Layoffs With Double Bonus Structure For Executives

In the last three months, 4 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $124.0, a high estimate of $132.00, and a low estimate of $100.00. This current average has increased by 14.29% from the previous average price target of $108.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175266_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$132.00</td>
<td>$119.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$132.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Hold</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Intra-Cellular Therapies's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intra-Cellular Therapies analyst ratings.</a>
<h2>Get to Know Intra-Cellular Therapies Better</h2>
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
<h3>Understanding the Numbers: Intra-Cellular Therapies's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of 39.23% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -15.03%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.3%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -1.99%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ITCI

Intra-Cellular Therapies Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $17.38, a high estimate of $18.50, and a low estimate of $15.00. Marking an increase of 9.79%, the current average surpasses the previous average price target of $15.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175259_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Pediatrix Medical Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.50</td>
<td>$16.50</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Tao Qiu</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Outperform</td>
<td>$18.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pediatrix Medical Group. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Pediatrix Medical Group compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Pediatrix Medical Group's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Pediatrix Medical Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pediatrix Medical Group analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Pediatrix Medical Group: A Closer Look</h2>
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment and generates majority of the revenue through neonatology and other pediatric subspecialties.
<h3>Key Indicators: Pediatrix Medical Group's Financial Health</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Pediatrix Medical Group's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 0.9%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Pediatrix Medical Group's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.8%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Pediatrix Medical Group's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.7%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pediatrix Medical Group's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Pediatrix Medical Group's debt-to-equity ratio is below the industry average at 0.93, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 4 Analysts Discuss Pediatrix Medical Group Stock

In the latest quarter, 4 analysts provided ratings for ESAB (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESAB#NYSE">ESAB</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $137.25, with a high estimate of $160.00 and a low estimate of $125.00. Marking an increase of 3.98%, the current average surpasses the previous average price target of $132.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175246_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive ESAB. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tami Zakaria</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$133.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$125.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Nathan Jones</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$131.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Saree Boroditsky</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$160.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to ESAB. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of ESAB compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of ESAB's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of ESAB's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ESAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on ESAB analyst ratings.</a>
<h2>Unveiling the Story Behind ESAB</h2>
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2023.
<h3>Unraveling the Financial Story of ESAB</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Negative Revenue Trend: Examining ESAB's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -1.14% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: ESAB's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 10.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 3.85%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): ESAB's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.7%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 0.64, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ESAB

Forecasting The Future: 4 Analyst Projections For ESAB

Providing a diverse range of perspectives from bullish to bearish, 8 analysts have published ratings on Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Builders FirstSource and provided 12-month price targets. The average target is $181.88, accompanied by a high estimate of $230.00 and a low estimate of $162.00. This current average has decreased by 9.58% from the previous average price target of $201.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175236_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Builders FirstSource by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Dahl</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Keith Hughes</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Charles Perron-Piche</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Reuben Garner</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$170.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Sam Darkatsh</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$170.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Matthew Bouley</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$188.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>W. Andrew Carter</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$175.00</td>
<td>-</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Builders FirstSource. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Builders FirstSource compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Builders FirstSource's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Builders FirstSource's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BLDR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Builders FirstSource analyst ratings.</a>
<h2>Delving into Builders FirstSource's Background</h2>
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
<h3>Builders FirstSource: A Financial Overview</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Challenges: Builders FirstSource's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately -6.66%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Builders FirstSource's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 6.73%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 6.51%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Builders FirstSource's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 2.63%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Builders FirstSource's debt-to-equity ratio stands notably higher than the industry average, reaching 0.98. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLDR

Where Builders FirstSource Stands With Analysts

During the last three months, 6 analysts shared their evaluations of Sonoco Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SON#NYSE">SON</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sonoco Prods and provided 12-month price targets. The average target is $61.17, accompanied by a high estimate of $71.00 and a low estimate of $50.00. Experiencing a 0.7% decline, the current average is now lower than the previous average price target of $61.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175227_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Sonoco Prods's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>George Staphos</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Gabe Hajde</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$50.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$63.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sonoco Prods. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sonoco Prods compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sonoco Prods's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sonoco Prods's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SON/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sonoco Prods analyst ratings.</a>
<h2>All You Need to Know About Sonoco Prods</h2>
Over its 100-year-plus history, Sonoco Products has steadily assembled a diverse portfolio of industrial and consumer packaging product offerings such as flexible and rigid plastics, reels and spools, pallets, and composite cans. The company serves a variety of consumer and industrial end markets throughout North America. Sonoco has raised its dividend each year for more than 40 years.
<h3>Unraveling the Financial Story of Sonoco Prods</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sonoco Prods's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -18.65%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -3.15%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -1.8%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sonoco Prods's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.4% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Sonoco Prods's debt-to-equity ratio stands notably higher than the industry average, reaching 3.19. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Sonoco Prods's Future

Analysts' ratings for Sabra Health Care REIT (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBRA#NASDAQ">SBRA</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sabra Health Care REIT and provided 12-month price targets. The average target is $19.25, accompanied by a high estimate of $20.00 and a low estimate of $17.00. Observing a downward trend, the current average is 0.41% lower than the prior average price target of $19.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1740175216_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Sabra Health Care REIT by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Carletti</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Aaron Hecht</td>
<td>JMP Securities</td>
<td>Announces</td>
<td>Market Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Vikram Malhotra</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sabra Health Care REIT. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sabra Health Care REIT compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Sabra Health Care REIT's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sabra Health Care REIT's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SBRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sabra Health Care REIT analyst ratings.</a>
<h2>All You Need to Know About Sabra Health Care REIT</h2>
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
<h3>Sabra Health Care REIT's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Sabra Health Care REIT showcased positive performance, achieving a revenue growth rate of 11.6% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Sabra Health Care REIT's net margin excels beyond industry benchmarks, reaching 25.61%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sabra Health Care REIT's ROE stands out, surpassing industry averages. With an impressive ROE of 1.7%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sabra Health Care REIT's ROA excels beyond industry benchmarks, reaching 0.88%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.89, Sabra Health Care REIT adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SBRA

A Glimpse Into The Expert Outlook On Sabra Health Care REIT Through 4 Analysts

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 15 years by 2.13% on an annualized basis producing an average annual return of 13.97%. Currently, Stryker has a market capitalization of $146.06 billion. 
Buying $100 In SYK: If an investor had bought $100 of SYK stock 15 years ago, it would be worth $720.87 today based on a price of $382.78 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740175213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) has outperformed the market over the past 5 years by 10.15% on an annualized basis producing an average annual return of 24.07%. Currently, Deere has a market capitalization of $133.45 billion. 
Buying $100 In DE: If an investor had bought $100 of DE stock 5 years ago, it would be worth $285.10 today based on a price of $489.98 for DE at the time of writing.
<h3>Deere's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1740174309_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Deere 5 Years Ago Would Be Worth This Much Today

&nbsp;
reAlpha Tech Corp. (the "Company") has estimated its total revenue for the three months ended December 31, 2024, to be in the range of approximately $0.5 million to $0.6 million. The Company's estimated total revenue for the year ended December 31, 2024, is projected to be in the range of approximately $0.9 million to $1.0 million.
&nbsp;
The Company had cash of approximately $3.1 million as of December 31, 2024, a decrease of approximately $3.9 million from approximately $7.0 million as of September 30, 2024. This decrease in cash was primarily due to the Company's cash payment of $1.5 million to the sellers of Debt Does Deals, LLC, d/b/a Be My Neighbor ("BMN"), on October 1, 2024, and the Company's increased operating expenses related to BMN following its acquisition.
&nbsp;
This preliminary unaudited financial data has been prepared by, and is the responsibility of, the Company's management and is based on preliminary and unaudited information currently available to the Company as well as management's estimates as of the date of this Current Report on Form 8-K. The Company's actual financial results may differ materially from the estimated preliminary unaudited financial data set forth above and will not be finalized until after the Company completes its normal year-end accounting procedures. As a result, no undue reliance should be placed on these preliminary estimates. GBQ Partners, LLC ("GBQ"), the Company's independent registered public accounting firm, has not audited, reviewed, compiled or performed any procedures with respect to this estimated preliminary financial data. Accordingly, GBQ does not express an opinion or any other form of assurance with respect thereto.

Earnings

Guidance

AIRE

ReAlpha Tech Estimates Its Total Revenue For The Three Months Ended December 31, 2024, To Be In The Range Of ~$0.5M-$0.6M; Estimated Total Revenue For The Year Ended December 31, 2024, Is Projected To Be In The Range Of ~$0.9M-$1M

Canaccord Genuity analyst Katie Lachapelle maintains Cameco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCO#TSX">CCO</a>) with a Buy and lowers the price target from C$85 to C$82.5.

Price Target

TSX:CCO

Canaccord Genuity Maintains Buy on Cameco, Lowers Price Target to C$82.5

Press Releases

China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency

Comments

China SXT Pharmaceuticals

China SXT Pharmaceuticals (SXTC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga